arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

RHYTHM PHARMACEUTICALS, INC.

RYTM

$115.67 ▲ +3.61 (+3.22%) at close

12 Visible periods

30 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

RHYTHM PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $7.5B

Dividend Yield —

Revenue Growth 45.8% ↘

Op. Margin -101.2% ↗

ROIC -80.2% ↗

FCF / Share $-1.79 ↗

Trailing P/E —

Price / Book 55.9x

FCF Yield —

Debt / Equity 0.73

info Valuation on last close. End-of-day price, Aug 7, 2026.

12-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$189.76M

↑ +45.8% —

Net Income Profit after all expenses

$-196.54M

↑ +24.6% —

Operating Margin Operating profit as % of sales

-101.2%

↑ +50.4% 2th

FCF / Share Free cash flow per share

$-1.79

↑ +3.9% —

Long-Term Debt Long-term obligations

$100.89M

↓ -6.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↓

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Revenue Growth YoY (%)	45.8% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+473%)	68.1% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+751%)	227.6% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2744%)	649.5% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+8018%)	—	—	—	—	—	—	—	—
EPS Growth YoY (%)	28.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-35.6% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	7.8% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-147.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	53.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	24.6% Good ↑ Good Improving Year-over-year change in net income	-41.1% Weak ↓ Weak Declining Year-over-year change in net income	-2.0% Weak ↑ Weak Improving Year-over-year change in net income	-160.2% Weak ↓ Weak Declining Year-over-year change in net income	48.0% Excellent ↑ Excellent Improving Year-over-year change in net income	4.8% Caution ↑ Caution Improving Year-over-year change in net income	-90.0% Weak → Weak Stable Year-over-year change in net income	-119.7% Weak ↓ Weak Declining Year-over-year change in net income	-30.3% Weak Weak Year-over-year change in net income	-133.6% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	3.9% Caution ↓ Caution Declining Year-over-year change in free cash flow	20.9% Good ↑ Good Improving Year-over-year change in free cash flow	29.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-12.9% Weak Weak Year-over-year change in free cash flow	-6.6% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	100.2% Excellent Excellent Compound annual revenue growth over 3 years	245.5% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Operating Margin (%) (%)	-101.2% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-775%)	-204.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1460%)	-238.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1687%)	—	—	—	—	—	—	—	—	—
Effective Tax Rate (%) (%)	-0.3% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.3% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—	—	—
Profit Margin (%) (%)	-103.6% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-963%)	-200.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1769%)	-238.5% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2088%)	—	—	—	—	—	—	—	—	—
FCF Margin (%) (%)	-61.5% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-87.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-175.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—	—	—
FCF / Net Income (x)	0.59x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.44x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	2.10x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.63x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Return on Invested Capital (%)	-80.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-204.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-67.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-53.6% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-47.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-64.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-41.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-25.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	62.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	104.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-40.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-67.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-55.4% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-46.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-51.6% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-73.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-47.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-30.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-21.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-209.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-141.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1042%)	—	-108.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-825%)	-68.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-557%)	-24.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-263%)	-80.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-636%)	-50.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-434%)	-30.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-301%)	-23.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-255%)	79.1% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+427%)	138.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+823%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Debt to Equity (x)	0.73x Fair ↓ Fair Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+21%)	4.98x Weak Weak Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+730%)	0.63x Fair Fair Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: At sector avg	—	—	—	—	—	—	—	—	—
Interest Coverage (x)	—	—	—	-34.45x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—	—	—
Net Debt (USD)	$46.59M	$19.13M	$46.06M	$-127.68M	$-59.25M	$-100.85M	$-62.29M	$-49.54M	$-34.24M	$-6.54M	$-34.87M	$-152.00K
Debt / EBITDA (x)	-0.53x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.41x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.58x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Revenue per Share (USD)	$2.92	$2.13	$1.34	$0.45	$0.06	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-3.11	$-4.34	$-3.20	$-3.47	$-1.40	$-3.04	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-1.79	$-1.87	$-2.36	$-3.33	$-2.95	$-2.77	—	—	—	—	—	—
Book Value per Share (USD)	$2.07	$0.35	$2.86	$4.67	$5.65	$3.76	$6.39	$7.16	$5.31	$-3.21	—	—
Tangible Book Value per Share (USD)	$2.07	$0.35	$2.86	$4.67	$5.65	$3.76	$6.39	$7.16	$5.31	$-3.21	—	—
Basic Weighted Avg Shares (shares)	64.98M	61.00M	57.67M	52.12M	49.60M	44.13M	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Working Capital (USD)	$360.97M	$258.68M	$253.06M	$314.43M	$264.96M	$163.67M	$277.99M	$245.11M	$143.95M	$6.44M	—	—
LT Debt (USD)	$100.89M	$108.27M	$106.14M	—	—	—	—	—	—	—	—	—
Total Equity (USD)	$139.07M	$21.73M	$169.76M	$264.26M	$284.15M	$166.53M	$281.02M	$246.26M	$144.79M	$-32.70M	$-8.00M	$-358.00K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Sales/Revenue/Turnover (USD)	$189.76M	$130.13M	$77.43M	$23.64M	$3.15M	—	$0.00	$0.00	$0.00	$0.00	—	—
Depreciation Expense (USD)	$500.00K	$700.00K	$903.00K	$896.00K	$816.00K	$690.00K	$834.00K	$442.00K	$223.00K	$144.00K	—	—
Net Income, GAAP (USD)	$-196.54M	$-260.60M	$-184.68M	$-181.12M	$-69.61M	$-134.00M	$-140.73M	$-74.06M	$-33.71M	$-25.87M	$-11.07M	—
Operating Cash Flow (USD)	$-115.67M	$-113.88M	$-136.16M	$-173.43M	$-146.00M	$-121.98M	$-122.75M	$-62.06M	$-29.46M	$-23.22M	$-6.98M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 41 quarters

RHYTHM PHARMACEUTICALS, INC.

Analytical Summary

12-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare RYTM with peers